Incyte Corporation (INCY) — Stock Score Summary

Incyte Corporation (INCY) has a MoatMap StockRank of 98/100 based on Quality (86/100), Value (47/100), and Momentum (61/100) factor scores. The current signal is STRONG BUY. Incyte, as a pharmaceutical and biotech company, directly benefits from the 'Healthcare Technology & Resilience' macro theme, which identifies defensive growth and undervalued opportunities in companies with robust R&D pipelines. The non-discretionary demand for healthcare, coupled with technological innovation leading to new treatments, provides a powerful and durable tailwind that the market may be underpricing, aligning with quality compounder characteristics.

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics, primarily in oncology and inflammation/autoimmunity. The company possesses a robust pipeline of innovative small-molecule drugs and a flagship product, Jakafi, which holds a leading market position in myelofibrosis and polycythemia vera. It is a leading biopharmaceutical innovator, recognized for its contributions to oncology and inflammatory disease treatments.

Key Financial Metrics

Price$97.16
Market Cap$19.4B
P/E (TTM)13.50
P/E (Forward)10.56
Price/Book3.40
Return on Equity30.8%
Return on Invested Capital30.6%
Debt/Equity0.70
Gross Margin52.8%
Operating Margin25.6%
Revenue Growth20.9%
Free Cash Flow$559M

Incyte Corporation operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Incyte Corporation’s (INCY) StockRank?
MoatMap’s StockRank for Incyte Corporation (INCY) is 98/100, with a Strong Buy signal. It is a composite of Quality (86), Value (47), and Momentum (61) factor ranks across MoatMap’s 19,000+ stock universe.
Does Incyte Corporation have an economic moat?
Incyte Corporation (INCY) has a Quality factor score of 86/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Incyte Corporation a buy, hold, or sell?
MoatMap’s current signal for Incyte Corporation (INCY) is Strong Buy, based on a StockRank of 98/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Incyte Corporation in?
Incyte Corporation (INCY) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksINCY deep dive reportAI ChampionsHow we score stocksSense-check another stock